10 research outputs found
PC-3 cells were cultured in serum-free medium for 24 h and then treated with or without cycloheximide (CHX, 5 μg/ml) for 1 hour prior to zinc (15 μM) exposure for 6 hours
<p><b>Copyright information:</b></p><p>Taken from "The Involvement of Bax in Zinc-Induced Mitochondrial Apoptogenesis in Malignant Prostate Cells"</p><p>http://www.molecular-cancer.com/content/7/1/25</p><p>Molecular Cancer 2008;7():25-25.</p><p>Published online 10 Mar 2008</p><p>PMCID:PMC2329666.</p><p></p
The cells were treated with medium supplemented with 15 μM zinc for 180 minutes versus no zinc treatment
<p><b>Copyright information:</b></p><p>Taken from "The Involvement of Bax in Zinc-Induced Mitochondrial Apoptogenesis in Malignant Prostate Cells"</p><p>http://www.molecular-cancer.com/content/7/1/25</p><p>Molecular Cancer 2008;7():25-25.</p><p>Published online 10 Mar 2008</p><p>PMCID:PMC2329666.</p><p></p
PC-3 cells were transfected with Bax siRNA or with empty vector and cultured for 72 hours; followed by treatment of the cells with 15 μM zinc for 24 hours
<p><b>Copyright information:</b></p><p>Taken from "The Involvement of Bax in Zinc-Induced Mitochondrial Apoptogenesis in Malignant Prostate Cells"</p><p>http://www.molecular-cancer.com/content/7/1/25</p><p>Molecular Cancer 2008;7():25-25.</p><p>Published online 10 Mar 2008</p><p>PMCID:PMC2329666.</p><p></p
The isolated mitochondria were exposed to medium supplemented with 15 μM zinc for 15 minutes or with unsupplemented medium (control)
<p><b>Copyright information:</b></p><p>Taken from "The Involvement of Bax in Zinc-Induced Mitochondrial Apoptogenesis in Malignant Prostate Cells"</p><p>http://www.molecular-cancer.com/content/7/1/25</p><p>Molecular Cancer 2008;7():25-25.</p><p>Published online 10 Mar 2008</p><p>PMCID:PMC2329666.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-6
Om each time point were separated by SDS-PAGE, and the MT 3 was detected by Western blot analysis (top panel) with rabbit anti-MT 3 antibody and β-actin was used as an internal control. The density of specific MT 3 signals was analyzed and data are shown on the lower panel. The experiment was repeated at least thrice.<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-0
M for 3 h. Thirty microliters of each cellular sample (200 mg of protein) were placed in a 96-well plate and the fluorescence of zinc labeled by TSQ was detected with a Microplate Reader (Fluoroskan Ascent, Labsystems).<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-8
M for 3 h. Thirty microliters of each cellular sample (200 mg of protein) were placed in a 96-well plate and the fluorescence of zinc labeled by TSQ was detected with a Microplate Reader (Fluoroskan Ascent, Labsystems).<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-1
-MT1/2 antibody, and β-actin was used as an internal control (top panel). The density of specific signals of MT1/2 was analyzed and data are presented in lower panel. The different letters (a, b, c) represent the statistical significance (p < 0.05).<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-5
Ed by Western blot analysis with rabbit anti-MT 3 antibody, and β-actin was used as an internal control (Top panel). The density of specific MT 3 signals was analyzed as described in the Materials and Methods, and the data are shown on the lower panel. The experiment was repeated at least thrice.<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p
Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues-7
Cells. The malignant tissues (G & H) appear to be negative to MT 1/2 staining in most of the cells with a few scattered stained cells. Control (A) was stained without primary MT 1/2 antibody. Immunoreactivity in a mixed tissue (B) of malignancy and BPH is indicated by arrows. Magnifications: 200-fold (B, C, E, G) and 400-fold (A, D, F, H)<p><b>Copyright information:</b></p><p>Taken from "Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues"</p><p>http://www.molecular-cancer.com/content/7/1/7</p><p>Molecular Cancer 2008;7():7-7.</p><p>Published online 21 Jan 2008</p><p>PMCID:PMC2265743.</p><p></p